
Please try another search
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Sergey B. Zotchev | - | - | Chief Scientific Officer and Member of Scientific Advisory Panel |
Marianne Kock | 70 | 2021 | Independent Deputy Chairperson |
Mattias Klintemar | 58 | 2021 | Board Member |
Robert Molander | 60 | 2024 | Independent Board Member |
Marco Taglietti | 65 | 2025 | Director |
Anna Ljung | 45 | 2024 | Independent Chairperson |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review